Cure My Disease

Don't miss your cure!

 Log in / Sign up

Immunotherapy may let some hodgkin lymphoma patients avoid intensive chemo and radiation

NCT ID NCT07720011

Disease control Sponsor: Peking University People's Hospital Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed This study
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jul 22, 2026 · Last updated Jul 23, 2026 · Updated 1 time

Summary

This phase 2 trial tests a personalized approach for people with newly diagnosed, advanced classical Hodgkin lymphoma. After two cycles of standard chemotherapy, patients are grouped based on a PET scan. Those with a moderate response receive the immunotherapy drug sintilimab plus a milder chemotherapy, aiming to avoid high-dose chemotherapy and radiation. The study will track how well this strategy controls the cancer and whether it reduces side effects.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
sintilimab (an anti-PD-1 immunotherapy) combined with AVD chemotherapy
What this could lead to
If successful, this approach could allow some Hodgkin lymphoma patients to avoid high-dose chemotherapy and radiation, reducing long-term side effects.
What could go wrong
This is a single-institution phase 2 trial, so results may not apply broadly. Adding immunotherapy may cause immune-related side effects, and it is not yet known if it will be as effective as standard treatment.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Phase 2

Tests whether the treatment actually works, and watches for side effects, in a larger group.

Participants

130 people

The number who actually took part.

Started

Feb 2019

Finished

Feb 2026

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Age ≥ 18 years old; * Histologically confirmed newly diagnosed classical Hodgkin lymphoma (cHL); * Eligible to receive standard frontline ABVD induction chemotherapy for 2 cycles; * Able to complete interim PET-CT (iPET2) scan after 2 cycles ABVD for Deauville score stratification; * Adequate bone marrow, hepatic and renal function to tolerate chemotherapy and immunotherapy; * Life expectancy ≥ 6 months at enrollment; * Willing to comply with scheduled treatment, imaging follow-up and laboratory tests; Exclusion Criteria: * Prior systemic anti-lymphoma therapy, including chemotherapy, radiation, anti-PD-1/PD-L1 immunotherapy or stem cell transplantation; * Severe irreversible organ dysfunction (cardiac, pulmonary, hepatic, renal) that cannot tolerate cytotoxic chemotherapy; * Known hypersensitivity to doxorubicin, bleomycin, vinblastine, dacarbazine or sintilimab; * Active severe infection (e.g., uncontrolled sepsis, active tuberculosis, HIV infection); * Pregnant or breastfeeding female patients; * Inability to complete serial PET-CT imaging due to contraindications such as severe contrast allergy

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Classical Hodgkin lymphoma are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

classic Hodgkin lymphoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Classical Hodgkin lymphoma

Contacts and locations

Locations

  • Peking University People's Hospital

    Beijing, China

More trials for these conditions

Other studies related to the condition(s) this trial covers.